|Bid||25.00 x 2900|
|Ask||26.15 x 800|
|Day's Range||25.14 - 27.79|
|52 Week Range||12.71 - 42.16|
|Beta (5Y Monthly)||1.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 08, 2022 - Aug 12, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||76.57|
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...
-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of safety results from the ongoing Phase I clinical study of CCX559, the Company’s highly potent, orally administered PD-L1 checkpoint